Assessment of Aging-Related Function Variations of P-gp Transporter in Old-Elderly Chinese CHF Patients Based on Modeling and Simulation

[1]  Zhu Zhu,et al.  Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation , 2021, Heart and Vessels.

[2]  Yang Zhang,et al.  Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions , 2021, CPT: pharmacometrics & systems pharmacology.

[3]  Rajendra Singh,et al.  Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague , 2021, British journal of clinical pharmacology.

[4]  N. Ali,et al.  Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases , 2021, Scientific Reports.

[5]  T. Prueksaritanont,et al.  Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach , 2021, Frontiers in Pharmacology.

[6]  Joshua D. Brown,et al.  Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate , 2021, CPT: pharmacometrics & systems pharmacology.

[7]  Dongyang Liu,et al.  Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects , 2020, British journal of clinical pharmacology.

[8]  S. Houterman,et al.  Dabigatran trough concentrations in very elderly patients , 2020, European journal of hospital pharmacy : science and practice.

[9]  Michael E. Lassman,et al.  A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment , 2020, Clinical pharmacology and therapeutics.

[10]  Diane D. Wang,et al.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies , 2020, Clinical Pharmacokinetics.

[11]  T. Murakami,et al.  Modulation of expression/function of intestinal P-glycoprotein under disease states , 2019, Expert opinion on drug metabolism & toxicology.

[12]  T. Eissing,et al.  Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin , 2019, CPT: pharmacometrics & systems pharmacology.

[13]  H. Allore,et al.  Are China’s oldest-old living longer with less disability? A longitudinal modeling analysis of birth cohorts born 10 years apart , 2019, BMC Medicine.

[14]  A. Rostami-Hodjegan,et al.  Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling , 2019, CPT: pharmacometrics & systems pharmacology.

[15]  D. Tweedie,et al.  Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P‐gp Inhibition , 2018, Clinical pharmacology and therapeutics.

[16]  P. Galajda,et al.  Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences , 2018, Drugs & Aging.

[17]  A. Galetin,et al.  Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[18]  Jie Liu,et al.  Age-associated differences in transporter gene expression in kidneys of male rats. , 2017, Molecular medicine reports.

[19]  S. Läer,et al.  Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows–A Physiologically Based Pharmacokinetic Approach , 2016, Drug Metabolism and Disposition.

[20]  Junzhou Fu,et al.  Evaluation of glomerular filtration rate by different equations in Chinese elderly with chronic kidney disease , 2016, International Urology and Nephrology.

[21]  T. Nakanishi,et al.  Interaction of Drug or Food with Drug Transporters in Intestine and Liver. , 2015, Current drug metabolism.

[22]  Miles C. Miller,et al.  P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations , 2015, Neurobiology of Aging.

[23]  Stephanie Läer,et al.  A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows , 2015, Clinical Pharmacokinetics.

[24]  Thomas Ebner,et al.  In Vitro Predictability of Drug-Drug Interaction Likelihood of P-Glycoprotein-Mediated Efflux of Dabigatran Etexilate Based on [I]2/IC50 Threshold , 2014, Drug Metabolism and Disposition.

[25]  A. Nader,et al.  Suitability of digoxin as a P‐glycoprotein probe: Implications of other transporters on sensitivity and specificity , 2014, Journal of clinical pharmacology.

[26]  H. Echizen,et al.  Clinical Pharmacokinetics of Drugs in Patients with Heart Failure: An Update (Part 2, Drugs Administered Orally) , 2013, Clinical Pharmacokinetics.

[27]  Masoud Jamei,et al.  Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. , 2013, Journal of pharmaceutical sciences.

[28]  K Rowland-Yeo,et al.  Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development , 2013, CPT: pharmacometrics & systems pharmacology.

[29]  Manuel Serrano,et al.  The Hallmarks of Aging , 2013, Cell.

[30]  Yuan Chen,et al.  Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.

[31]  S. Yusuf,et al.  Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial , 2011, Journal of thrombosis and haemostasis : JTH.

[32]  E. Yukawa,et al.  Determination of Digoxin Clearance in Japanese Elderly Patients for Optimization of Drug Therapy , 2011, Drugs & aging.

[33]  Jun Li,et al.  Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice , 2010, Acta Pharmacologica Sinica.

[34]  M. Fromm,et al.  ATP-binding cassette transporters in human heart failure , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[35]  B. Blumberg,et al.  Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues , 2005, Molecular and Cellular Endocrinology.

[36]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[37]  L. Benet,et al.  Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. , 2003, Current drug metabolism.

[38]  T. Murakami,et al.  Expression and function of P‐glycoprotein in rats with carbon tetrachloride‐induced acute hepatic failure , 2001, The Journal of pharmacy and pharmacology.

[39]  G. D. Johnston,et al.  Differential Pharmacokinetics of Digoxin in Elderly Patients , 2000, Drugs & aging.

[40]  N. Bricker,et al.  The pathologic physiology of chronic Bright's disease. An exposition of the "intact nephron hypothesis". , 1997, The American journal of medicine.